Treatment of breast cancer cell lines with ERAP led to rapid dissociation of PHB2 captured by BIG3 and thereby rapid, E2-dependent PHB2 phosphorylation at Ser39, allowing reactivation of the innate suppressive capability of PHB2. The gene discussed is ARFGEF3; the disease is breast carcinoma.